I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Antibody-based therapies targeting IL1RAP

For treatment of cancer and autoimmune and inflammatory diseases

Our projects

Cantargia presents at Redeye Fight Cancer

To the presentation

Cantargia presents at BioStock Life Science Fall Summit 2022

To the presentation
Press releases

2023-02-01 (R) Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

2023-01-13 (R) Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application

2022-11-21 (R) Nomination Committee appointed ahead of 2023 Annual General Meeting

(R) = Regulatory press releases

”Cantargia is in a strong position with many upcoming milestones in our two development programs. The presentations at the ASCO conference during 2022 generated a lot of attention, and we have very exciting times ahead of us.”

Göran Forsberg
CEO Cantargia
Analysis

2022-11-11, Redeye analysis of Cantargia

2022-09-02, Aktiespararna analysis of Cantargia (In Swedish)

2022-08-31, Edison analysis of Cantargia

2022-08-31, Redeye analysis of Cantargia

Presentations

2023-01-19, Video, Redeye Fight Cancer 2022

2022-12-02, Video, Investment day, Västra Hamnen Corporate Finance (In Swedish)

2022-11-30, Video, BioStock Life Science Fall Summit 2022

2022-11-24, Video, Redeye Life Science Day 2022 (In Swedish)

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2023 · Cantargia AB